Beam Therapeutics
BEAMNASDAQBase editing genetic medicine platform
Drafted with AI assistance from public sources and not individually reviewed by an editor; last updated 2026-04-09. Published by ClinicalInvestor. Educational analysis only. Read the editorial policy and disclosures.
text updated 2026-04-09, 222 days ago · archived: kept for reference, not maintained · where each field comes from
Key figures from SEC filings
Upcoming catalysts
Company-specific dates below are registry milestones or filings we have linked. For FDA decision dates site-wide, see the PDUFA calendar.
BEAM-302 AATD: BEAM-302 in Alpha-1 antitrypsin deficiency — primary completion
2028-05
Registry milestone — the date data collection is scheduled to end, not when results are released. ClinicalTrials.gov
BEAM-301 GSDIa: BEAM-301 in Glycogen storage disease type Ia — primary completion
2027-12-30
Registry milestone — the date data collection is scheduled to end, not when results are released. ClinicalTrials.gov
BEAM-201 T-ALL: BEAM-201 in Relapsed/refractory T-ALL or T-LL — primary completion
2026-12
Registry milestone — the date data collection is scheduled to end, not when results are released. ClinicalTrials.gov
Pipeline
| Drug | Indication | Phase | Expected data | |
|---|---|---|---|---|
| BEAM-101 | sickle cell disease | Phase 1 | Not disclosed | ▼ |
| BEAM-302 | alpha-1 antitrypsin deficiency | Phase 1 | Not disclosed | ▼ |
| BEAM-103 | beta thalassemia | Preclinical | Not disclosed | ▼ |
Analysis
Comparable companies
Sponsored
Get premium BEAM analysis on Seeking AlphaAffiliate link — we may earn a commission at no cost to you